Credit Suisse said in a research report that it cut Alibaba Health Information Technology's revenue growth and gross profit margin from HK $15 to HK $11 and maintained its "outperform" rating.

According to the report, Alibaba Health Information Technology's net loss in the first half of the year was lower than the bank expected. Management guidelines 2022 FY24 revenue growth of about 30%, gross revenue stable profit. Exploration of new businesses, such as proprietary pharmacies and personalized insurance, is under way. The bank does not expect to launch an online prescription drug sales policy this year, but the policy could affect revenue growth by several percentage points.